Regulation of the T Cell Response by CD39

Trends in Immunology

Volumn 37, Issue 7, 2016, Pages 427-439

  Takenaka, Maisa C ^a   Robson, Simon ^b   Quintana, Francisco J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; EXTRACELLULAR ADENOSINE TRIPHOSPHATE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 27; PURINERGIC P2Y RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ADENOSINE; ADENOSINE PHOSPHATE; APYRASE; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; APOPTOSIS; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL KINETICS; CELL MOTILITY; CELLULAR IMMUNITY; DENDRITIC CELL; ENZYME DEGRADATION; ENZYME RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ANIMAL; AUTOIMMUNE DISEASE; GENOTYPE ENVIRONMENT INTERACTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; T LYMPHOCYTE;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE MONOPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GENE-ENVIRONMENT INTERACTION; HUMANS; IMMUNE TOLERANCE; INFECTION; INFLAMMATION; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 84969641306     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.04.009     Document Type: Review

References (122)

1. 1 Eltzschig, H.K., et al. Purinergic signaling during inflammation. N. Engl. J. Med. 367 (2012), 2322–2333.
2. 2 Junger, W.G., Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11 (2011), 201–212.
3. 3 Robson, S.C., et al. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2 (2006), 409–430.
4. 4 Horenstein, A.L., et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology, 2, 2013, e26246.
5. 5 Trautmann, A., Extracellular ATP in the immune system: more than just a ‘danger signal’. Sci. Signal., 2, 2009, pe6.
6. 6 Burnstock, G., Boeynaems, J.M., Purinergic signalling and immune cells. Purinergic Signal. 10 (2014), 529–564.
7. 7 Filippini, A., et al. Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc. Natl. Acad. Sci. U.S.A. 87 (1990), 8267–8271.
8. 8 Ledderose, C., et al. Mitochondrial dysfunction, depleted purinergic signaling, and defective T cell vigilance and immune defense. J. Infect. Dis. 213 (2016), 456–464.
9. 9 Schenk, U., et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal., 1, 2008, ra6.
10. 10 Woehrle, T., et al. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood 116 (2010), 3475–3484.
11. 11 Chekeni, F.B., et al. Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis. Nature 467 (2010), 863–867.
12. 12 Qu, Y., et al. Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J. Immunol. 186 (2011), 6553–6561.
13. 13 Cotrina, M.L., et al. Connexins regulate calcium signaling by controlling ATP release. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 15735–15740.
14. 14 Eltzschig, H.K., et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ. Res. 99 (2006), 1100–1108.
15. 15 Pearson, R.A., et al. ATP released via gap junction hemichannels from the pigment epithelium regulates neural retinal progenitor proliferation. Neuron 46 (2005), 731–744.
16. 16 Schena, F., et al. Dependence of immunoglobulin class switch recombination in B cells on vesicular release of ATP and CD73 ectonucleotidase activity. Cell Rep. 3 (2013), 1824–1831.
17. 17 Atarashi, K., Honda, K., Microbiota in autoimmunity and tolerance. Curr. Opin. Immunol. 23 (2011), 761–768.
18. 18 Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157 (2014), 121–141.
19. 19 Garrett, W.S., Cancer and the microbiota. Science 348 (2015), 80–86.
20. 20 Inoue, Y., Shimojo, N., Microbiome/microbiota and allergies. Semin. Immunopathol. 37 (2015), 57–64.
21. 21 Li, Y., et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147 (2011), 629–640.
22. 22 Smith, P.M., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341 (2013), 569–573.
23. 23 Zelante, T., et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39 (2013), 372–385.
24. H17 cell differentiation. Nature 455 (2008), 808–812.
25. 25 Sansom, F.M., et al. Possible effects of microbial ecto-nucleoside triphosphate diphosphohydrolases on host–pathogen interactions. Microbiol. Mol. Biol. Rev. 72 (2008), 765–781.
26. 26 Wang, Y., et al. An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling. Nat. Commun., 5, 2014, 4432.
27. 27 Idzko, M., et al. Nucleotide signalling during inflammation. Nature 509 (2014), 310–317.
28. 28 Bono, M.R., et al. CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. FEBS Lett. 589 (2015), 3454–3460.
29. 29 Sevigny, J., et al. Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99 (2002), 2801–2809.
30. 30 Gordon, E.L., et al. The hydrolysis of extracellular adenine nucleotides by cultured endothelial cells from pig aorta. Feed-forward inhibition of adenosine production at the cell surface. J. Biol. Chem. 261 (1986), 15496–15507.
31. 31 Candinas, D., et al. Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb. Haemost. 76 (1996), 807–812.
32. 32 Robson, S.C., et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J. Exp. Med. 185 (1997), 153–163.
33. 33 Di Virgilio, F., et al. Extracellular nucleotides as negative modulators of immunity. Curr. Opin. Pharmacol. 9 (2009), 507–513.
34. 34 Yip, L., et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 23 (2009), 1685–1693.
35. 35 Wang, C.M., et al. Adenosine triphosphate acts as a paracrine signaling molecule to reduce the motility of T cells. EMBO J. 33 (2014), 1354–1364.
36. + T cells via purinergic P2 receptor activation. J. Immunol. 189 (2012), 1303–1310.
37. 37 Tsukimoto, M., et al. P2X7 receptor-dependent cell death is modulated during murine T cell maturation and mediated by dual signaling pathways. J. Immunol. 177 (2006), 2842–2850.
38. 38 Josefowicz, S.Z., et al. Regulatory T cells: mechanisms of differentiation and function. Ann. Rev. Immunol. 30 (2012), 531–564.
39. + T regulatory cell-mediated suppression. Immunity 30 (2009), 636–645.
40. 40 Wing, K., et al. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 32 (2011), 428–433.
41. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110 (2007), 1225–1232.
42. 42 Deaglio, S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204 (2007), 1257–1265.
43. 43 Liao, H., et al. cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J. Biol. Chem. 285 (2010), 14791–14805.
44. 44 Schenk, U., et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci. Signal., 4, 2011, ra12.
45. reg balance by hypoxia-inducible factor 1. Cell 146 (2011), 772–784.
46. 46 Semenza, G.L., Hypoxia-inducible factors in physiology and medicine. Cell 148 (2012), 399–408.
47. 47 Semenza, G.L., Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Ann. Rev. Pathol. 9 (2014), 47–71.
48. 48 Amoroso, F., et al. The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis., 3, 2012, e370.
49. 49 Sun, X., et al. Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice. Hepatology 57 (2013), 205–216.
50. 50 Roederer, M., et al. The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis. Cell 161 (2015), 387–403.
51. 51 Hatfield, S.M., et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. 92 (2014), 1283–1292.
52. + regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J. Immunol. 175 (2005), 3075–3083.
53. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997), 737–742.
54. 54 Clayton, A., et al. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 187 (2011), 676–683.
55. 55 Roncarolo, M.G., et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212 (2006), 28–50.
56. 56 Roncarolo, M.G., et al. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr. Topics Microbiol. Immunol. 380 (2014), 39–68.
57. 57 Astier, A.L., Hafler, D.A., Abnormal Tr1 differentiation in multiple sclerosis. J. Neuroimmunol. 191 (2007), 70–78.
58. 58 Awasthi, A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 8 (2007), 1380–1389.
59. 59 Stumhofer, J.S., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8 (2007), 1363–1371.
60. 60 Fitzgerald, D.C., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8 (2007), 1372–1379.
61. 61 Apetoh, L., et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11 (2010), 854–861.
62. 62 Farez, M.F., et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162 (2015), 1338–1352.
63. + regulatory T cells. Nat. Immunol. 11 (2010), 846–853.
64. 64 Wu, H.Y., et al. In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS ONE, 6, 2011, e23618.
65. 65 Mascanfroni, I.D., et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. Nat. Med. 21 (2015), 638–646.
66. 66 Vaughn, B.P., et al. Purinergic signaling in liver disease. Dig. Dis. 32 (2014), 516–524.
67. 67 Quintana, F.J., Sherr, D.H., Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol. Rev. 65 (2013), 1148–1161.
68. 7 receptor. Bioorg. Med. Chem. Lett. 21 (2011), 5475–5479.
69. 69 Gaublomme, J.T., et al. Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. Cell 163 (2015), 1400–1412.
70. 70 Lee, Y., et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13 (2012), 991–999.
71. H-17 cell-mediated pathology. Nat. Immunol. 8 (2007), 1390–1397.
72. 72 Wang, C., et al. CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell 163 (2015), 1413–1427.
73. 73 Codarri, L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12 (2011), 560–567.
74. H17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12 (2011), 568–575.
75. 75 Chalmin, F., et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36 (2012), 362–373.
76. + Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS ONE, 9, 2014, e87956.
77. 77 Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15 (2015), 486–499.
78. + T cells. PLoS Pathog., 11, 2015, e1005177.
79. 79 Hindupur, S.K., et al. The opposing actions of target of rapamycin and AMP-activated protein kinase in cell growth control. Cold Spring Harb. Perspect. Biol., 7, 2015, a019141.
80. + T cells: predominant role of PDE4D. J. Immunol. 178 (2007), 4820–4831.
81. 2A receptor expression by LPS: analysis of the 5′ upstream promoter. Genes Immun. 14 (2013), 147–153.
82. 82 Kreth, S., et al. Differential expression of 5′-UTR splice variants of the adenosine A2A receptor gene in human granulocytes: identification, characterization, and functional impact on activation. FASEB J. 22 (2008), 3276–3286.
83. 83 Burgueno, J., et al. The adenosine A2A receptor interacts with the actin-binding protein alpha-actinin. J. Biol. Chem. 278 (2003), 37545–37552.
84. 84 Gsandtner, I., et al. Heterotrimeric G protein-independent signaling of a G protein-coupled receptor. Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A adenosine receptor is necessary for sustained activation of the ERK/MAP kinase pathway. J. Biol. Chem. 280 (2005), 31898–31905.
85. 85 Keuerleber, S., et al. From cradle to twilight: the carboxyl terminus directs the fate of the A2A-adenosine receptor. Biochim. Biophys. Acta 1808 (2011), 1350–1357.
86. 86 Milojevic, T., et al. The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. Mol. Pharmacol. 69 (2006), 1083–1094.
87. 2A adenosine receptor via a novel interacting protein, translin-associated protein X. Mol. Pharmacol. 70 (2006), 454–466.
88. 88 Deaglio, S., Robson, S.C., Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 61 (2011), 301–332.
89. + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139 (2010), 1030–1040.
90. 90 Beavis, P.A., et al. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 33 (2012), 231–237.
91. 91 Martins, I., et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 8 (2009), 3723–3728.
92. 92 Vieira, C., et al. Feed-forward inhibition of CD73 and upregulation of adenosine deaminase contribute to the loss of adenosine neuromodulation in postinflammatory ileitis. Mediators Inflamm., 2014, 2014, 254640.
93. 93 Ganguly, D., et al. The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 13 (2013), 566–577.
94. 94 Amit, I., et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science 326 (2009), 257–263.
95. 95 Garber, M., et al. A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol. Cell 47 (2012), 810–822.
96. 96 Mariathasan, S., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 (2006), 228–232.
97. 97 Shih, V.F., et al. A single NFkappaB system for both canonical and non-canonical signaling. Cell Res. 21 (2011), 86–102.
98. 98 Mascanfroni, I.D., et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14 (2013), 1054–1063.
99. 99 Watanabe, H., et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J. Invest. Dermatol. 127 (2007), 1956–1963.
100. 100 Eisenbarth, S.C., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008), 1122–1126.
101. 101 Meng, G., et al. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30 (2009), 860–874.
102. 102 Gris, D., et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 185 (2010), 974–981.
103. 103 Mizumoto, N., et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat. Med. 8 (2002), 358–365.
104. 104 Melillo, J.A., et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J. Immunol. 184 (2010), 2638–2645.
105. 105 Moore, K.W., et al. Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. 19 (2001), 683–765.
106. 106 Van Belle, T.L., et al. Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 36 (2012), 1060–1072.
107. 107 Baker, B.J., et al. IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 58 (2010), 1082–1093.
108. 108 Farber, K., et al. The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia 56 (2008), 331–341.
109. 109 Iyer, S.S., et al. Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J. Immunol. 185 (2010), 6599–6607.
110. 110 Marteau, F., et al. Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotide diphosphates on human monocyte-derived dendritic cells. J. Leukoc. Biol. 76 (2004), 796–803.
111. 7 receptor characterized in murine dendritic cells: role on the induction of apoptosis. Blood 96 (2000), 996–1005.
112. + regulatory T cell-suppressive function and therapeutic efficacy. Mucosal Immunol. 9 (2016), 137–145.
113. 113 Hall, A.O., et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 37 (2012), 511–523.
114. 114 Stumhofer, J.S., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7 (2006), 937–945.
115. 115 Villegas-Mendez, A., et al. IL-27 receptor signalling restricts the formation of pathogenic, terminally differentiated Th1 cells during malaria infection by repressing IL-12 dependent signals. PLoS Pathog., 9, 2013, e1003293.
116. 116 Müller, T., et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation. Allergy 65 (2010), 1545–1553.
117. 117 Idzko, M., et al. Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br. J. Pharmacol. 138 (2003), 1244–1250.
118. 118 Chen, Y., et al. Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci. Signal., 3, 2010, ra45.
119. 119 Elliott, M.R., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461 (2009), 282–286.
120. 120 Idzko, M., et al. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 100 (2002), 925–932.
121. 121 Heiss, K., et al. High sensitivity of intestinal CD8+ T cells to nucleotides indicates P2X7 as a regulator for intestinal T cell responses. J. Immunol. 181 (2008), 3861–3869.
122. 122 Lévesque, S.A., et al. NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur. J. Immunol. 40 (2010), 1473–1485.